1. REGN stock fell 19% after itepekimab's trial failure. 2. The stock is down 60% from its 52-week high. 3. REGN's valuation may indicate a buying opportunity. 4. Eylea received FDA rejection, adding to REGN's challenges. 5. Dupixent shows promising growth, potentially offsetting setbacks.
The failure of itepekimab and Eylea's FDA rejection significantly pressure REGN's stock. Past similar events have led to prolonged declines.
The article highlights significant setbacks affecting REGN's key products and market perception. Future performance hinges on overcoming these challenges, especially concerning upcoming trials.
Immediate negative effects from the trial failure will likely be felt soon. However, future sales potential of Dupixent could provide longer-term recovery.